Federal Judge Pauses Kennedy's Changes to Childhood Vaccine Schedule
via HealthDayTUESDAY, March 17, 2026 — A federal judge has stopped a major effort to change the nation’s childhood vaccine schedule.
The ruling, issued Monday in Massachusetts, blocks U.S. Health Secretary Robert F. Kennedy Jr.’s plan to revise vaccine recommendations for children.
The decision stems from a lawsuit brought by several medical groups against the U.S. Department of Health and Human Services (HHS).
The lawsuit was organized by the American Academy of Pediatrics (AAP) and other organizations. They argued that Kennedy’s changes to vaccine guidance and a vaccine advisory group violated federal law.
Earlier this year, Kennedy and the U.S. Centers for Disease Control and Prevention (CDC) overhauled the childhood vaccine schedule. The update decreased the number of diseases for which routine childhood vaccines are recommended from 18 to 11.
Under the revamped schedule, vaccines for several illnesses were no longer recommended for all children. These included hepatitis A, hepatitis B, RSV, dengue and two forms of bacterial meningitis.
Many doctors and public health experts strongly opposed the change.
More than 200 organizations, including the American Medical Association, the March of Dimes and the Autism Science Foundation, said they would ignore the new federal schedule.
Instead, they said they would continue following the AAP’s recommended vaccine schedule.
The judge’s decision also paused changes that Kennedy made to the CDC’s Advisory Committee on Immunization Practices (ACIP).
This panel plays a major role in shaping U.S. vaccine policy. Its recommendations influence both the childhood vaccine schedule and which vaccines insurance companies must cover.
In June, Kennedy removed all 17 members of the panel and replaced them with new appointees, many of whom are vaccine critics.
The committee had planned to meet this week. The judge’s ruling effectively cancels that meeting.
The ruling also freezes votes taken by the new committee members, including one to no longer recommend the hepatitis B vaccine for all newborns.
Critics of the Kennedy-led changes hailed the decision.
“Today is a day to celebrate the triumph of science over misinformation,” Dr. Richard Besser, president of the Robert Wood Johnson Foundation, told NBC News. “This is a huge blow to Kennedy’s vaccine policies.”
AAP President Dr. Andrew Racine said the ruling “re-established a degree of clarity” about childhood vaccinations.
“If anyone has any questions about what’s the appropriate vaccine schedule for their children, the best thing to do is to talk to their pediatricians,” he said.
HHS spokesperson Andrew Nixon said the government “looks forward to this judge’s decision being overturned just like his other attempts to keep the Trump administration from governing.”
Richard Hughes, attorney for the AAP, suggested the case could eventually reach the U.S. Supreme Court.
Since taking office, Kennedy, a long-time vaccine critic, has endorsed several changes to federal vaccine policy. These include stricter rules for vaccine testing and limits on who can receive certain COVID-19 vaccines, especially those using mRNA technology.
Others say those policies have created confusion and weakened public trust in vaccines.
A recent survey from the Annenberg Public Policy Center at the University of Pennsylvania found trust in public health agencies has declined during President Donald Trump’s second term.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-18 02:00
Read more
- Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
- FDA Provides Fast Track Designation to Nipocalimab for Systemic Lupus Erythematosus
- Food Stamp Users Fight Restrictions on Soda and Sweets
- ACC/AHA Guidelines Updated for Dyslipidemia Management
- Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
- Beren Therapeutics Announces FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann Pick Disease Type C
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions